Summary
| Diagnosis | Sex | Age | Nationality |
|---|---|---|---|
| Autism | Female | 9 years | USA |
| Injections | Cell type | Admission date | Discharge date |
| 8 | UCBSC + UCMSC | June 12th 2024 | June 22nd 2024 |
Medical history
The patient was diagnosed with Autism Spectrum Disorder (ASD) in 2018 and has since received various treatments aimed at managing symptoms and supporting developmental progress. Treatment history includes repetitive Transcranial Magnetic Stimulation (rTMS), fecal microbiota transplantation (FMT), primitive reflex exercises, hippotherapy, hyperbaric oxygen therapy (HBOT), and an extensive list of medications and supplements such as Namenda, Carnitor, Ubiquinol, Leucovorin, and Omega supplements. Additional therapies have included red light therapy, detoxification methods, acupuncture, chelation therapy, and several others targeting neurological and immune health. Past stem cell therapy treatments were administered in June 2022, December 2022, and May 2023, showing incremental improvements in communication skills, cognition, mood, and social interactions. The patient has also been treated for ADHD and experiences occasional nosebleeds, minor pain, seasonal cough, eczema, and susceptibility to frequent infections.
Condition On Admission
The patient currently exhibits several symptoms associated with ASD, including social deficits, speech delay, echolalia, cognitive and attention issues, and a lack of social awareness. Additionally, the patient has ADHD symptoms, occasional urinary accidents, difficulties waking up in the morning, and experiences non-restorative sleep with minor sleep apnea. Physical symptoms include frequent respiratory and skin infections, eczema, dark circles under the eyes, and susceptibility to bruising and inflammation-related rashes. She has a known allergy to Bactrim, which causes skin flare-ups, and although past constipation issues have largely resolved with magnesium and FMT treatment, she occasionally experiences skipped bowel movements. The family hopes for improvements in her speech, cognitive skills, autoimmune stability, and overall skin health with continued treatment.
Treatment Schedule
Patient received 8 packs of umbilical cord derived stem cells (UCMSC) and umbilical cord blood derived stem cells (UCBSC) by intravenous (IV) injection and intrathecal injection via lumbar puncture (LP), as per the schedule below:
| Number | Date | Cell Type | Delivery Method | Side Effects |
|---|---|---|---|---|
| 1 | 2024-06-12 | UCMSC | Intrathecal Injection & Intravenous Injection |
none reported |
| 2 | 2024-06-15 | UCMSC + UCBSC | Intravenous Injection & Intravenous Injection |
none reported |
| 3 | 2024-06-18 | UCMSC | Intrathecal Injection & Intravenous Injection |
none reported |
| 4 | 2024-06-21 | UCBSC | Intravenous Injection & Intravenous Injection |
none reported |
Condition 1 month after treatment
After one month of stem cell treatment, the patient showed moderate improvement in general physical health, particularly regarding recurring bruise-like rashes that subsided, which may indicate a reduction in autoimmune-related symptoms. There has been a slight improvement in overall quality of life, but the observed improvements have now stabilized. Although specific symptoms showed varying levels of improvement, no new illnesses or accidents were reported, and no additional treatments have been required. The family reports being somewhat satisfied with the treatment outcomes, noting particular areas with small to moderate improvements in certain social and developmental behaviors.
| Symptom | Parents’ Assessment of Improvement |
|---|---|
| Cooperation with others | Moderate improvement |
| Using more than one word at a time | Moderate improvement |
| Appropriate facial expressions | Small improvement |
| Asking questions | Small improvement |
| Aware of environment | Small improvement |
| Interaction with others | Small improvement |
| Plays appropriately | Small improvement |
| Responding to commands | Small improvement |
Condition at discharge
Three months following stem cell treatment, the patient continues to experience moderate improvements in general physical and emotional well-being. Positive changes include a more stable mood, increased energy, easier morning routines, and improved body movement, particularly noticeable in ballet class. Recurring bruise-like rashes, previously seen from February to June, have not returned, which aligns with earlier improvements in autoimmune symptoms. While the treatment outcome continues to yield small to moderate improvements in several social and communicative behaviors, there have been no doctor-confirmed improvements, and the family reports being somewhat satisfied with the progress.
| Symptom | Parents’ Assessment of Improvement |
|---|---|
| Comfortable with physical contact | Moderate improvement |
| Cooperation with others | Moderate improvement |
| Expressing own needs | Moderate improvement |
| General conversation | Moderate improvement |
| General mood | Moderate improvement |
| Responding to commands | Moderate improvement |
| Showing imagination | Moderate improvement |
| Temper tantrums | Moderate improvement |
| Uses greetings | Moderate improvement |
| Using more than one word at a time | Moderate improvement |